Morgan Stanley lowered the firm’s price target on Halozyme (HALO) to $79 from $80 and keeps an Overweight rating on the shares. Halozyme has not yet scheduled a date to report Q3 earnings, but the firm continues to believe that strength in royalties and cost discipline will drive EPS outperformance for the remainder of 2025, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme’s Strong Royalty Revenue and Strategic Initiatives Justify Buy Rating Despite Potential Risks
- Halozyme’s Strong Financial Outlook and Strategic Investment Potential Amidst Policy Stability
- Halozyme upgraded at Leerink on lower-than-feared Part B exposure
- Halozyme upgraded to Market Perform from Underperform at Leerink
- Halozyme Confirms Minimal Impact from Medicare Guidance